Which has better valuation and earnings, DFTX or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$2.49 N/A Celcuity N/A N/A -$177.04M -$3.90 N/A

Is DFTX or CELC more profitable?

Definium Therapeutics' return on equity of -100.30% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -100.30% -69.22% Celcuity N/A -244.61% -50.22%

Does the media favor DFTX or CELC?

In the previous week, Celcuity had 24 more articles in the media than Definium Therapeutics. MarketBeat recorded 26 mentions for Celcuity and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.94 beat Celcuity's score of 0.22 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 6 Very Negative mention(s) Neutral

Does the media favor HIMS or DFTX?

In the previous week, Hims & Hers Health had 19 more articles in the media than Definium Therapeutics. MarketBeat recorded 21 mentions for Hims & Hers Health and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.94 beat Hims & Hers Health's score of 0.84 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 7 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PACS or DFTX?

In the previous week, Definium Therapeutics had 1 more articles in the media than PACS Group. MarketBeat recorded 2 mentions for Definium Therapeutics and 1 mentions for PACS Group. Definium Therapeutics' average media sentiment score of 0.94 beat PACS Group's score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DFTX or CAI?

In the previous week, Caris Life Sciences had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 3 mentions for Caris Life Sciences and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.94 beat Caris Life Sciences' score of 0.40 indicating that Definium Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DFTX or BLLN more profitable?

Billiontoone's return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -100.30% -69.22% Billiontoone N/A N/A N/A

Does the media prefer DFTX or BLLN?

In the previous week, Definium Therapeutics and Definium Therapeutics both had 2 articles in the media. Billiontoone's average media sentiment score of 1.38 beat Definium Therapeutics' score of 0.94 indicating that Billiontoone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Definium Therapeutics (DFTX) Competitors

$24.58 +0.99 (+4.20%)

As of 06/4/2026 03:58 PM Eastern

Compare

DFTX vs. CELC, HIMS, PACS, CAI, and BLLN

Should you buy Definium Therapeutics stock or one of its competitors? MarketBeat compares Definium Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Definium Therapeutics include Celcuity (CELC), Hims & Hers Health (HIMS), PACS Group (PACS), Caris Life Sciences (CAI), and Billiontoone (BLLN). These companies are all part of the "healthcare" industry.

How does Definium Therapeutics compare to Celcuity?

Definium Therapeutics (NASDAQ:DFTX) and Celcuity (NASDAQ:CELC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Celcuity had 24 more articles in the media than Definium Therapeutics. MarketBeat recorded 26 mentions for Celcuity and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.94 beat Celcuity's score of 0.22 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	6 Very Negative mention(s)	Neutral

Definium Therapeutics presently has a consensus target price of $37.92, suggesting a potential upside of 54.28%. Celcuity has a consensus target price of $152.09, suggesting a potential upside of 64.48%. Given Celcuity's higher possible upside, analysts plainly believe Celcuity is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Definium Therapeutics' return on equity of -100.30% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Celcuity	N/A	-244.61%	-50.22%

Definium Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

Celcuity is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Summary

Definium Therapeutics beats Celcuity on 8 of the 14 factors compared between the two stocks.

How does Definium Therapeutics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Hims & Hers Health had 19 more articles in the media than Definium Therapeutics. MarketBeat recorded 21 mentions for Hims & Hers Health and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.94 beat Hims & Hers Health's score of 0.84 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	7 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics has a net margin of 0.00% compared to Hims & Hers Health's net margin of -0.56%. Hims & Hers Health's return on equity of 6.10% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Definium Therapeutics	N/A	-100.30%	-69.22%

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hims & Hers Health has higher revenue and earnings than Definium Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.77	$128.37M	-$0.09	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

Hims & Hers Health has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

Hims & Hers Health presently has a consensus target price of $28.70, indicating a potential upside of 2.21%. Definium Therapeutics has a consensus target price of $37.92, indicating a potential upside of 54.28%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Definium Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Hims & Hers Health beats Definium Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to PACS Group?

PACS Group (NYSE:PACS) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

PACS Group presently has a consensus price target of $48.00, indicating a potential upside of 28.05%. Definium Therapeutics has a consensus price target of $37.92, indicating a potential upside of 54.28%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

PACS Group has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.43B	1.09	$191.54M	$1.56	24.03
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

27.9% of Definium Therapeutics shares are owned by institutional investors. 70.1% of PACS Group shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Definium Therapeutics had 1 more articles in the media than PACS Group. MarketBeat recorded 2 mentions for Definium Therapeutics and 1 mentions for PACS Group. Definium Therapeutics' average media sentiment score of 0.94 beat PACS Group's score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PACS Group has a net margin of 4.49% compared to Definium Therapeutics' net margin of 0.00%. PACS Group's return on equity of 26.47% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Definium Therapeutics	N/A	-100.30%	-69.22%

Summary

PACS Group beats Definium Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Caris Life Sciences?

Definium Therapeutics (NASDAQ:DFTX) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Caris Life Sciences has a net margin of 3.75% compared to Definium Therapeutics' net margin of 0.00%. Caris Life Sciences' return on equity of 98.28% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Caris Life Sciences	3.75%	98.28%	48.87%

27.9% of Definium Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Caris Life Sciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Caris Life Sciences	$812.03M	6.02	-$68.09M	-$7.61	N/A

Definium Therapeutics presently has a consensus target price of $37.92, indicating a potential upside of 54.28%. Caris Life Sciences has a consensus target price of $27.56, indicating a potential upside of 59.47%. Given Caris Life Sciences' higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Caris Life Sciences had 1 more articles in the media than Definium Therapeutics. MarketBeat recorded 3 mentions for Caris Life Sciences and 2 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.94 beat Caris Life Sciences' score of 0.40 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Caris Life Sciences beats Definium Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Billiontoone?

Definium Therapeutics (NASDAQ:DFTX) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Definium Therapeutics and Definium Therapeutics both had 2 articles in the media. Billiontoone's average media sentiment score of 1.38 beat Definium Therapeutics' score of 0.94 indicating that Billiontoone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Billiontoone has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Billiontoone	$354.54M	13.57	$7.45M	$0.55	190.16

Billiontoone's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Billiontoone	N/A	N/A	N/A

Definium Therapeutics presently has a consensus price target of $37.92, indicating a potential upside of 54.28%. Billiontoone has a consensus price target of $125.29, indicating a potential upside of 19.79%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Definium Therapeutics is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Billiontoone beats Definium Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DFTX vs. The Competition

Export

Metric	Definium Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.35B	$376.12M	$6.30B	$12.43B
Dividend Yield	N/A	3.87%	2.69%	5.32%
P/E Ratio	-9.87	3.21	23.73	24.34
Price / Sales	N/A	6,668.35	496.68	95.47
Price / Cash	N/A	13.13	41.39	55.53
Price / Book	7.32	85.78	10.04	6.72
Net Income	-$183.79M	-$96.07M	$3.56B	$337.03M
7 Day Performance	1.61%	-0.77%	-1.01%	-0.16%
1 Month Performance	9.73%	2.11%	2.21%	3.74%
1 Year Performance	219.64%	75.77%	28.96%	34.34%

Definium Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DFTX Definium Therapeutics	3.0992 of 5 stars	$24.58 +4.2%	$37.92 +54.3%	+221.3%	$2.35B	N/A	N/A	40
CELC Celcuity	3.2179 of 5 stars	$122.96 -7.5%	$150.27 +22.2%	+671.9%	$6.48B	N/A	N/A	40	Trending News Analyst Forecast Analyst Revision
HIMS Hims & Hers Health	2.5958 of 5 stars	$27.77 +6.2%	$28.70 +3.3%	-47.8%	$6.05B	$2.35B	N/A	2,442
PACS PACS Group	4.027 of 5 stars	$35.55 -3.0%	$48.00 +35.0%	+268.9%	$5.80B	$5.29B	22.79	47,455
CAI Caris Life Sciences	4.7895 of 5 stars	$16.45 -1.6%	$27.56 +67.5%	N/A	$4.73B	$812.03M	N/A	1,846

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DFTX) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Definium Therapeutics (DFTX) Competitors

DFTX vs. CELC, HIMS, PACS, CAI, and BLLN

How does Definium Therapeutics compare to Celcuity?

Summary

How does Definium Therapeutics compare to Hims & Hers Health?

Summary

How does Definium Therapeutics compare to PACS Group?

Summary

How does Definium Therapeutics compare to Caris Life Sciences?

Summary

How does Definium Therapeutics compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Definium Therapeutics (DFTX) Competitors

DFTX vs. CELC, HIMS, PACS, CAI, and BLLN

How does Definium Therapeutics compare to Celcuity?

Do insiders and institutionals hold more shares of DFTX or CELC?

Does the media favor DFTX or CELC?

Do analysts prefer DFTX or CELC?

Is DFTX or CELC more profitable?

Which has more volatility and risk, DFTX or CELC?

Which has better valuation and earnings, DFTX or CELC?

Summary

How does Definium Therapeutics compare to Hims & Hers Health?

Does the media favor HIMS or DFTX?

Is HIMS or DFTX more profitable?

Do insiders & institutionals have more ownership in HIMS or DFTX?

Which has higher earnings & valuation, HIMS or DFTX?

Which has more volatility and risk, HIMS or DFTX?

Do analysts recommend HIMS or DFTX?

Summary

How does Definium Therapeutics compare to PACS Group?

Do analysts prefer PACS or DFTX?

Which has higher valuation and earnings, PACS or DFTX?

Do insiders and institutionals believe in PACS or DFTX?

Does the media prefer PACS or DFTX?

Is PACS or DFTX more profitable?

Summary

How does Definium Therapeutics compare to Caris Life Sciences?

Is DFTX or CAI more profitable?

Do institutionals & insiders have more ownership in DFTX or CAI?

Which has stronger valuation and earnings, DFTX or CAI?

Do analysts recommend DFTX or CAI?

Does the media prefer DFTX or CAI?

Summary

How does Definium Therapeutics compare to Billiontoone?

Do institutionals and insiders have more ownership in DFTX or BLLN?

Does the media prefer DFTX or BLLN?

Which has higher earnings and valuation, DFTX or BLLN?

Is DFTX or BLLN more profitable?

Do analysts rate DFTX or BLLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DFTX vs. The Competition

Definium Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools